Ardelyx Inc
$ 5.56
2.96%
05 Jun - close price
- Market Cap 1,373,483,000 USD
- Current Price $ 5.56
- High / Low $ 5.64 / 5.39
- Stock P/E N/A
- Book Value 0.60
- EPS -0.24
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.40 %
- 52 Week High 8.40
- 52 Week Low 3.49
About
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Analyst Target Price
$16.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-19 | 2025-10-30 | 2025-08-04 | 2025-05-01 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-10-31 | 2023-08-02 |
| Reported EPS | -0.15 | -0.0017 | -0.004 | -0.08 | -0.17 | 0.02 | -0.0034 | -0.07 | -0.11 | -0.12 | 0.03 | -0.08 |
| Estimated EPS | -0.14 | -0.0197 | -0.07 | -0.14 | -0.07 | -0.0007 | -0.05 | -0.11 | -0.16 | -0.09 | -0.11 | -0.11 |
| Surprise | -0.01 | 0.018 | 0.066 | 0.06 | -0.1 | 0.0207 | 0.0466 | 0.04 | 0.05 | -0.03 | 0.14 | 0.03 |
| Surprise Percentage | -7.1429% | 91.3706% | 94.2857% | 42.8571% | -142.8571% | 2957.1429% | 93.2% | 36.3636% | 31.25% | -33.3333% | 127.2727% | 27.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARDX
2026-06-05 20:09:25
Ardelyx (ARDX) has experienced a significant share price pullback, down 24% over the past month, leading investors to re-evaluate its valuation. Despite the short-term pressure, the stock is considered 66.9% undervalued with a fair value of US$16.33, primarily driven by expectations of rapid top-line expansion and growth in its core addressable markets due to an aging population and improved market access for its products, IBSRELA and XPHOZAH. Investors are encouraged to review the company's prospects and risks, including reliance on its key products and exposure to Medicare reimbursement.
2026-06-04 11:39:00
Ardelyx projects over $500 million in revenue for 2026, driven primarily by IBSRELA, its irritable bowel syndrome treatment, which is expected to bring in $410 million to $430 million. The company aims for $1 billion in IBSRELA revenue by 2029 and sees potential for profitability this year, although it is holding off on formal guidance until sustainability is confirmed. Growth strategies include an expanded sales force, enhanced prescription fulfillment via a specialty pharmacy network, and direct physician outreach.
2026-06-04 03:10:26
Ardelyx Inc. (ARDX) shares rose in after-hours trading following renewed guidance for its drug IBSRELA and expectations of profitability soon. The company anticipates combined revenue from IBSRELA and XPHOZAH to exceed $500 million this year, with a long-term target of $1 billion for IBSRELA by 2029. Ardelyx also outlined strategic priorities for 2026, including sales force expansion and advancing its pipeline, while retail sentiment remains bullish with analysts rating the stock a "Buy."
2026-06-03 16:09:42
Ardelyx, Inc. (ARDX) projects strong revenue growth for its drugs IBSRELA and XPHOZAH, with 2026 revenue expected to exceed $500 million. The company aims for long-term targets of $1 billion for IBSRELA and $750 million for XPHOZAH by 2029, supported by strategic investments in sales, marketing, R&D, and new patent protection, signaling confidence in sustained growth and near-term profitability. This outlook is based on insights from the Jefferies Global Healthcare Conference 2026.
2026-06-02 09:10:26
Ardelyx (ARDX) experienced a significant 58% year-over-year revenue growth in Q1 2026, primarily driven by its IBS-C therapy, IBSRELA. This growth, coupled with increased attention from AI-driven stock rankings, highlights the drug's strong commercial momentum. However, the company still faces challenges including a narrow product base, ongoing losses, and reimbursement uncertainties for its other key product, XPHOZAH, despite reiterating revenue guidance for 2026.
2026-06-01 13:09:29
Ardelyx reported a 58% year-over-year revenue growth in Q1 2026, primarily driven by its IBS-C therapy, IBSRELA, which has caught the attention of AI-driven stock rankings. The company's investment narrative focuses on the potential of IBSRELA and XPHOZAH to achieve profitability despite a narrow product base and reimbursement uncertainty, projecting significant revenue and earnings growth by 2029. This growth is anticipated to lead to a substantial upside in Ardelyx's stock value, according to fair value estimates.
